Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00032032 · ClinicalTrials.gov registry record · Phase 1
Combination Chemotherapy Plus Radiation Therapy in Treating Patients With Non-Small Cell Lung Cancer
A Phase 1 study of Lung Cancer, sponsored by Alliance for Clinical Trials in Oncology.
- Completed
- Registry status
- Phase 1
- Development phase
- 69
- Enrollment target
- 20
- Study locations
NCT00032032 is a Phase 1 study of Lung Cancer that has completed, run by Alliance for Clinical Trials in Oncology. The registered enrollment target is 69 participants, below the 936-participant average among 409 other Lung Cancer trials with a reported enrollment target (93% lower). The trial reports 20 study locations across 6 states.
The verdict
NCT00032032, a Phase 1 study of Lung Cancer, has completed, sponsored by Alliance for Clinical Trials in Oncology.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 69 participants
- Enrollment target
- 20
- Study locations
Study Summary
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Radiation therapy uses high-energy x-rays to damage tumor cells. Combining chemotherapy and radiation therapy may kill more tumor cells. PURPOSE: This phase I/II trial is studying the side effects and best dose of radiation therapy when given with combination chemotherapy and to see how well they work in treating patients with non-small cell lung cancer that cannot be surgically removed.
Conditions Studied
Interventions
- DRUG carboplatin
- DRUG paclitaxel
- RADIATION radiation therapy
Study Locations (20)
Iowa
- McFarland Clinic, PC - Ames
- Mercy Capitol Hospital - Des Moines
- CCOP - Iowa Oncology Research Association - Des Moines
- John Stoddard Cancer Center at Iowa Methodist Medical Center - Des Moines
- Medical Oncology and Hematology Associates at John Stoddard Cancer Center - Des Moines
- Medical Oncology and Hematology Associates at Mercy Cancer Center - Des Moines
- Mercy Cancer Center at Mercy Medical Center - Des Moines - Des Moines
- John Stoddard Cancer Center at Iowa Lutheran Hospital - Des Moines
- Siouxland Hematology-Oncology Associates, LLP - Sioux City
- Mercy Medical Center - Sioux City - Sioux City
- St. Luke's Regional Medical Center - Sioux City
Michigan
- Hickman Cancer Center at Bixby Medical Center - Adrian
- Haematology-Oncology Associates of Ohio and Michigan, PC - Lambertville
- Community Cancer Center of Monroe - Monroe
- Mercy Memorial Hospital - Monroe - Monroe
Minnesota
- MeritCare Bemidji - Bemidji
- Mayo Clinic Cancer Center - Rochester
Arizona
- Mayo Clinic Scottsdale - Scottsdale
Florida
- Mayo Clinic - Jacksonville - Jacksonville
Nebraska
- CCOP - Missouri Valley Cancer Consortium - Omaha
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 69 participants |
| Start Date | 2002-05 |
| Est. Completion | 2010-01 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00032032
The ClinicalTrials.gov registry entry for NCT00032032 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 69 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 936-participant average among 409 other Lung Cancer trials with a reported enrollment target (93% lower). The listed sponsor is Alliance for Clinical Trials in Oncology, which has 446 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Lung Cancer appearing as the primary indexed condition, and to 3 interventions - of which carboplatin is the first listed.
NCT00032032 reports 20 study locations spanning 6 distinct geographic areas - top geographies include Iowa, Michigan, Minnesota.
Frequently Asked Questions
What is clinical trial NCT00032032 about?
NCT00032032 is a clinical study titled "Combination Chemotherapy Plus Radiation Therapy in Treating Patients With Non-Small Cell Lung Cancer". RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Radiation therapy uses high-energy x-rays to damage tumor cells. Combining chemotherapy and radiation therapy may kill more tumor cells. PURPOSE: This phase I/II trial is studying...
What is the current status of trial NCT00032032?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 69 participants. The study started on 2002-05. Estimated completion is 2010-01.
What conditions does trial NCT00032032 study?
This clinical trial studies the following conditions: Lung Cancer.
What interventions are being tested in trial NCT00032032?
The interventions under investigation include: carboplatin (DRUG), paclitaxel (DRUG), radiation therapy (RADIATION).
Who is sponsoring clinical trial NCT00032032?
This trial is sponsored by Alliance for Clinical Trials in Oncology, which has 446 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00032032 being conducted?
This trial has 20 study locations across Arizona, Florida, Iowa, Michigan, Minnesota. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Lung Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Study Investigating BG-60366 in Adults With Epidermal Growth Factor Receptor (EGFR)-Mutant Non-Small Cell Lung Cancer
RECRUITING · Phase 1
-
KK-LC-1 TCR-T Cell Therapy for Gastric, Breast, Cervical, and Lung Cancer
RECRUITING · Phase 1
-
A Study to Evaluate the Safety, Tolerability, Drug Levels, and Preliminary Efficacy of BMS-986507 Combinations in Adult Participants With Advanced Solid Tumors
RECRUITING · Phase 1
-
Safety and Tolerability of TNG456 Alone and in Combination With Abemaciclib in Patients With Solid Tumors With MTAP Loss
RECRUITING · Phase 1
-
Safety, PK and Efficacy of QXL138AM in Patients With Solid Tumors and Multiple Myeloma
RECRUITING · Phase 1
-
Open Label Study to Evaluate BL-M07D1 in HER2 Expressing Malignant Solid Tumors
RECRUITING · Phase 1
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.